Press Releases<< Back
New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment
NCCN's guidelines update follows the recent publication of results of Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, led by
Additionally, the NCCN guidelines elevated Oncotype DX into the algorithm for chemotherapy treatment of patients with micrometastases and one to three positive lymph nodes.
"We are pleased NCCN continues to clearly distinguish Oncotype DX from other genomic tests based on clinical evidence and the critical importance of predicting chemotherapy benefit," said Steven Shak, M.D., chief scientific and medical officer, Genomic Health. "This new strengthened NCCN guidelines, combined with the recent inclusion of Oncotype DX in international guidelines, demonstrates global support for Oncotype DX as the only 'preferred' test to guide optimal treatment based on its unique ability to predict chemotherapy benefit."
NCCN is an alliance of 21 world-leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. The 2018 guidelines were published online this week.
About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score® test, is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score® test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score® test predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 900,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatement.org.
About Genomic Health
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the significance of molecular diagnostics in breast cancer treatment planning, the value of the individualized tumor information provided by Oncotype DX, the belief that the use of Oncotype DX has been accepted as standard practice for individualized breast cancer treatment decisions, and the ability of guidelines reports, including the recent publication of the 2018 NCCN guidelines, to influence or expand global reimbursement coverage and use of the Oncotype DX test. These risks and uncertainties include, but are not limited to: the applicability of clinical results to actual outcomes; the ability of our test to continue to impact treatment decisions; our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; the risk of delay in developing new products or product enhancements; the risks and uncertainties associated with the regulation of our test by
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-nccn-breast-cancer-guidelines-elevate-oncotype-dx-breast-recurrence-score-as-the-only-preferred-multi-gene-test-to-predict-chemotherapy-treatment-300728129.html
Investors: Emily Faucette, Genomic Health, 650-569-2824, email@example.com; Media (U.S. and Canada): Victoria Steiner, Genomic Health, 415-370-5804, firstname.lastname@example.org; Media (Asia, Europe, Latin America): Federico Maiardi, Genomic Health, +41 79 138 1326, email@example.com